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Conclusions: Renal-artery stenting does not confer signiﬁcant beneﬁt
with respect to prevention of clinical events when added to comprehensive,
multifactorial medical therapy in people with atherosclerotic renal-artery ste-
nosis and hypertension or chronic kidney disease.
Summary: Between 1996 and 2000, the annual number of renal-
artery stenting procedures in Medicare beneﬁciaries increased 364%
(Murphy TP et al, Am J Roentgenol 2004;183:561-8). However, subse-
quently randomized trials of renal-artery angioplasty failed to show beneﬁt
with respect to blood pressure (Plouin PF et al, Hypertension 1998;31:823-
9; and Webster J et al, J Hum Hypertens 1998;12:329-35). Two additional
trials did not show a beneﬁt of renal-artery stenting with respect to kidney
function (ASTRAL Investigators, N Engl J Med 2009;361:1953-62; and
Bax L et al, Ann Intern Med 2009;50:840-8). These trials were not specif-
ically designed to assess clinical outcomes. This trial, CORAL, was a ran-
domized clinical trial to determine the effects of renal-artery stenting on
the incidence of important renal adverse events and cardiovascular events.
There were 947 participants with atherosclerotic renal-artery stenosis and
either systolic hypertension taking two or more antihypertensive drugs or
chronic kidney disease randomly assigned to medical therapy plus renal-ar-
tery stenting or medical therapy alone. Study participants were followed for
occurrence of adverse cardiovascular and renal events (a composite end
point of death from cardiovascular or renal causes, myocardial infarction,
stroke, hospitalization for congestive heart failure, progressive renal insufﬁ-
ciency, or the need for renal-replacement therapy). The median follow-up
was 43 months (interquartile range, 31 to 55 months). The rate of the pri-
mary composite end point did not differ signiﬁcantly between participants
who underwent stenting in addition to receiving medical therapy and those
who received medical therapy alone (35.1 % and 35.8%, respectively; hazard
ratio with stenting, 0.94; 95% conﬁdence interval, 0.76-1.17; P ¼ .58).
There were also no signiﬁcant differences between treatment groups and
the rates of the individual components of the primary end point or in all-
cause mortality. There was during follow-up a consistent modest difference
in systolic blood pressure that favored the stent group (2.3 mm Hg; 95%
conﬁdence interval, 4.4 to 0.2; P ¼ .03).
Comment: Readers of the Journal of Vascular Surgery are referred to
the accompanying editorial in the same issue of the New England Journal of
Medicine by John A. Bittl, MD. Dr Bittl concludes “In conclusion, the
CORAL trial is a deﬁnitive test of the usefulness of renal-artery stents for
moderately severe atherosclerotic disease. The trial results send a clear mes-
sage to patients and referring physicians. Until new treatments are found to
be safe and effective, patients in every-day practice who have moderately se-
vere atherosclerotic renovascular disease and either hypertension or stage 3
chronic kidney disease should receive medical therapy to control blood pres-
sure and prevent the progression of atherosclerosis but should not be
corralled into getting a renal-artery stent”. Dr Bittl’s conclusion seems
entirely justiﬁed by the data presented.
Preoperative Statins and Limb Salvage After Lower Extremity
Revascularization in the Medicare Population
Vogel TR, Dombrovskiy VY, Galiñanes EL, et al. Circ Cardiovasc Interv
2013;6:694-700.
Conclusions: Preoperative statin use is associated with improved
1-year limb salvage after lower extremity revascularization. Statin medica-
tions appear to be underused among Medicare patients with peripheral
artery disease.
Summary: Statins have many pleotropic effects including enhance-
ment of ﬁbrinolysis, decreased platelet activity, inhibition of cell growth,
and potential reduction of ischemia-reperfusion injury, and restoration of
endothelial function (Ray KK et al, Curr Treat Options Cardiovasc Med
2007;9:46-51). Statin therapy appears to reduce all-cause mortality in pa-
tients with peripheral vascular disease undergoing major noncardiac vascular
surgery (Leurs LJ et al, Vascular 2006;14:1-8). Primary management goals
of patients with peripheral arterial disease (PAD) are to increase life and pro-
mote limb salvage. In this paper, the authors use Medicare data to evaluate
the association between statin therapy, limb salvage, and amputation in pa-
tients undergoing lower extremity PAD-related vascular procedures. Pa-
tients analyzed were selected from 2007 and 2008 Medicare claims using
the International Classiﬁcation of Diseases, Ninth Revision, Clinical Modi-
ﬁcation, diagnosis codes for claudication (n ¼ 8128), rest pain (n ¼ 3056),
and ulceration gangrene (n ¼ 11,770) and Current Procedural Terminol-
ogy (CPT) codes for endovascular revascularization (n ¼ 14,353) andopen surgery (n ¼ 8601). Half of the patients (n ¼ 11,687) were identiﬁed
as statin users before revascularization using Part D ﬁles. Amputations were
then identiﬁed using CPT codes. Statin users compared with nonusers had
lower amputation rates at 30 days (11.5% vs 14.4%; P < .0001), 90 days
(15.5% vs 19.3%; P < .0001), and 1 year (20.9% vs 25.6%; P < .0001). Sur-
vival analysis demonstrated improved limb salvage during 1 year for statin
users compared with nonusers for the diagnosis of claudication (P ¼
.003), a similar trend for rest pain (P ¼ .061), and no improvement for
ulceration/gangrene (P ¼ .65).
Comment: One has to be a bit suspicious about the results of this
study. While it is very likely the numbers are what they are, the idea that pa-
tients with claudication beneﬁt from statin therapy for limb salvage while
those with ulceration do not seems a bit counterintuitive. After all, the inci-
dence of amputation in patients with claudication at 1 year should be very
close to zero. Perhaps patients with ulceration and gangrene have such
advanced vascular disease that the statins cannot help with their lower ex-
tremity prognosis. However, these patients also likely have advanced coro-
nary and cerebral vascular disease, arguing all CLI patients should be on a
statin medication for those reasons alone.
Outpatient Endovascular Aortic Aneurysm Repair: Experience in 100
Consecutive Patients
Lachat ML, Pecoraro F, Mayer D, et al. Ann Surg 2013;258:754-9.
Conclusions: Elective endovascular aneurysm repair (EVAR) can be
safely performed as an outpatient procedure.
Summary: It is clear that 30-day operative mortality for EVAR can
be quite low, in some cases less 1% (Katzen BT et al, Circulation
2005;112:1663-75). The background of this paper is that the authors
claim a 16-year experience with more than 1000 EVAR cases. In their
opinion, in technically uncomplicated EVAR procedures, the only need
for postoperative hospitalization is for vessel access complications that
require secondary procedures. Their feeling is that these complications
should always be identiﬁed within the ﬁrst 3 hours after EVAR. Based
on these personal observations and a presentation by Dr Jacques Bleyn
at the 25th Charing Cross International Symposium in April 2003, the
authors felt it was reasonable to offer outpatient endovascular abdominal
aortic aneurysm repair to their patients. In this report, they review their
original experience in a 100-patient outpatient EVAR series. This was a
two-center retrospective analysis of apparently prospectively gathered
data on 100 consecutive outpatient EVAR cases. To be eligible for
outpatient EVAR, the patients had to be asymptomatic, provide
informed consent, have a travel time to the hospital for potential read-
mission of less than 60 minutes, have adult observer assistance for the
ﬁrst 24 hours, and have had undergone a technically uncomplicated
EVAR procedure. In their series, EVAR was most commonly performed
under local anesthesia with percutaneous access with patients discharged
home after 4 to 6 hours of observation. They were then re-examined the
next morning and on the ﬁfth postoperative day in the outpatient clinic.
There were 104 patients selected for outpatient EVAR. Four of these
(3.8%) preferred primary hospitalization and were excluded from addi-
tional analysis. Four patients also had access vessel complications that
required additional procedures and hospitalization overnight. The thir-
ty-day readmission rate was 4% (n ¼ 4) and this was all due to access
vessel complications such as stenosis (n ¼ 2) or false aneurysm (n ¼
2). There was no 30-day operative mortality in this series. Ninety-three
of the 96 patients who completed outpatient EVAR were said to have
been sufﬁciently satisﬁed that they would recommend it to other patients
as well. A cost comparison of 42 matched contemporary patients treated
with a standard stent graft protocol suggested that costs were signiﬁ-
cantly lower in 21 outpatient EVAR patients than in 21 inpatient
EVAR patients.
Comment: This study is essentially an analysis of the author’s attempt
to offer EVAR as an outpatient procedure. It does demonstrate that EVAR
is potentially feasible as an outpatient procedure. Of course, the patients
appear to be highly selected and while not hospitalized, must remain close
to the hospital for follow-up examination on the ﬁrst postoperative day. The
value of the paper is not so much in its science. There’s really no science
here. Undoubtedly, however, there will be an occasional patient, or perhaps
more than an occasional patient, who would prefer to go home the same day
as their aneurysm repair. This paper provides a bit of justiﬁcation for that
approach. The limitations on the patients placed by the authors for outpa-
tient EVAR indicate that for this approach to be successful, the patients
should be carefully selected with respect to both medical and social
variables.
